Donald Trump and Pharma
In the aftermath of one of the most controversial and highly publicized presidential elections, there already seems to be an unexpected effect: after the DOW dropped as many as 700 points the night of the election, the stock market, and the pharmaceutical industry as well, as seen substantial increases. For instance, major drug makers like Novartis and Sanofi, saw their stock prices rise between 2%-4.5%. Meanwhile, the stocks of biotech companies such as Biogen and Celgene, increased exponentially as well. While the Trump presidency hasn’t even started, many investors and individuals who work in the pharmaceutical industry are less concerned about a clampdown on prescription drug prices. The Trump administration has also publicly voiced it’s displease and will attempt to end Obamacare, which surely plays a factor as well. Meanwhile, the Clinton administration had been extremely critical of drug industry pricing, constantly criticizing the industry for its drug pricing practices as well as promises to curb prescription drug prices. Although still early, it will be interesting to see if these trends will follow as the new administration continues.
Source:
http://www.fiercepharma.com/pharma/pharma-loves-free-trade-how-will-it-get-along-a-protectionist-president-trump